Compelling Arguments for Including West Pharmaceutical Shares in Your Investment Portfolio Today

West Pharmaceutical Services, Inc.: Growth Outlook and Challenges

West Pharmaceutical Services, Inc. (WST) is poised for expansion, supported by robust demand for high-value product components, increasing GLP-1 drug initiatives, and regulatory changes such as Annex 1 conversions. Nevertheless, the company faces hurdles including tariff-related costs, inventory reductions in generic drugs, and operational difficulties at certain European sites.

Over the past six months, shares of this Zacks Rank #2 (Buy) company have declined by 11.3%, while the industry saw a 15.7% gain. In comparison, the S&P 500 Index rose 4.2% during the same period.

With a market value of $17.87 billion, West Pharmaceutical is a global leader in designing and manufacturing advanced containment and delivery solutions for injectable medications and healthcare products. Analysts expect its earnings to grow by 11.8% over the next five years, and the company has delivered an average earnings surprise of 17.39% across the last four quarters.

Image Source: Zacks Investment Research

Key Drivers Behind WST’s Growth

High-Value Product Component Demand

West Pharmaceutical continues to experience strong demand for its high-value product (HVP) components, fueled by the growth of biologics, GLP-1 therapies, and regulatory upgrades like Annex 1. Demand currently outpaces supply, prompting the company to expand its production capabilities.

Looking ahead to 2026, the company anticipates organic growth in HVP components ranging from high single digits to low double digits. Annex 1 conversions are generating numerous projects with global pharmaceutical partners, and HVP components offer margins two to three times greater than standard products. Management expects the HVP mix to increase by 100 basis points annually, enhancing profitability. By leveraging its existing infrastructure and expanding HVP-focused capacity, West Pharmaceutical is improving revenue predictability and long-term margin stability.

GLP-1 Therapeutics Expansion

The company is benefiting from the rapid expansion of GLP-1 drugs used for diabetes and obesity. Both oral and injectable GLP-1 formats are expected to drive future growth. Industry experts believe oral GLP-1s will broaden the market rather than replace injectables, as most new oral GLP-1 users are new to the category. Adoption remains in the early stages, with only a small percentage of eligible patients currently treated. As access improves, patient numbers are projected to increase significantly.

Various injectable delivery systems, such as auto-injectors and multi-dose pens, are expected to coexist based on preferences. The introduction of injectable GLP-1 generics in countries like India, China, Brazil, and Canada will further boost accessibility. These trends suggest sustained growth opportunities for both oral and injectable GLP-1 treatments.

Cash Flow and Margin Improvements

West Pharmaceutical is generating strong operating cash flow and seeing margin improvements, positioning it well for ongoing financial strength into 2026 and beyond. Management reports disciplined capital spending, with capital expenditures expected to normalize at 6-8% of sales, supporting continued cash generation. This financial flexibility enables investments in capacity, innovation, and operational enhancements as demand for high-value components rises.

Additionally, management anticipates more than 100 basis points of margin expansion in 2026, driven by a greater share of higher-margin HVP components and the sale of the SmartDose business. Upgrading customers to premium products and optimizing capital deployment should further support profitability and sustained earnings growth.

Challenges Facing West Pharmaceutical

Operational Limitations and Execution Risks

Despite strong demand, West Pharmaceutical is contending with short-term operational issues, particularly at a European HVP facility where hiring and training delays are restricting capacity. Management aims to resolve these challenges over the next 12-18 months through network optimization and technology transfers, but successful execution is crucial.

Delays could disrupt supply, strain customer relationships, and postpone revenue from high-margin projects. New manufacturing capacity, such as the Dublin facility, requires lengthy validation before full utilization, potentially slowing near-term growth and causing earnings volatility.

Industry Inventory Adjustments and Demand Normalization

The pharmaceutical packaging sector is still adjusting inventories after the pandemic-driven surge. West Pharmaceutical faces ongoing destocking, especially in generics and, to a lesser extent, biologics, impacting order volumes and masking underlying demand trends.

Management expects conditions to gradually normalize, but a prolonged destocking cycle could dampen short-term revenue growth. As demand stabilizes post-pandemic, the urgency for capacity expansion may decrease, resulting in more moderate growth and limited near-term revenue visibility.

West Pharmaceutical Services, Inc. Price

For detailed price information, visit West Pharmaceutical Services, Inc. price or view the West Pharmaceutical Services, Inc. Quote.

Analyst Estimate Trends

WST has seen upward revisions in earnings estimates for 2026. Over the past month, the Zacks Consensus Estimate for earnings increased by 2.3% to $7.85 per share, representing a 7.7% rise from the previous year. Revenue estimates are set at $3.25 billion, a 5.7% increase from 2025.

Other Notable Medical Stocks

• Intuitive Surgical (ISRG): Currently holds a Zacks Rank #1 (Strong Buy). Reported Q4 2025 adjusted EPS of $2.53, beating estimates by 12.4%. Revenues reached $2.87 billion, surpassing estimates by 4.7%. Long-term earnings growth is projected at 15.7%, compared to the industry’s 13.6%. The company exceeded earnings estimates in the last four quarters, with an average surprise of 13.2%.
• Phibro Animal Health (PAHC): Zacks Rank #2 (Buy). Q2 fiscal 2026 adjusted EPS was 87 cents, beating estimates by 27.1%. Revenues of $373.9 million exceeded estimates by 4.7%. Long-term earnings growth is estimated at 21.5%, versus the industry’s 12.2%. The company beat earnings estimates in the last four quarters, with an average surprise of 20.1%.
• Cardinal Health (CAH): Zacks Rank #2. Q2 fiscal 2026 adjusted EPS was $2.63, beating estimates by 10%. Revenues of $65.6 billion surpassed estimates by 0.9%. Long-term earnings growth is projected at 15%, compared to the industry’s 9.2%. The company exceeded earnings estimates in the last four quarters, with an average surprise of 9.3%.

Quantum Computing: The Next Tech Revolution

Quantum computing is emerging as a transformative technology, potentially surpassing artificial intelligence in impact. Once considered years away, it is now advancing rapidly, with major companies like Microsoft, Google, Amazon, Oracle, Meta, and Tesla racing to integrate quantum computing into their operations.

Senior Stock Strategist Kevin Cook has identified seven stocks poised to lead the quantum computing sector in his report, Beyond AI: The Quantum Leap in Computing Power. Kevin, who recognized NVIDIA’s potential early on, now highlights quantum computing as the next major investment opportunity. Investors have a unique chance to capitalize on this trend.

See Top Quantum Stocks Now >>

Get the Latest Stock Recommendations

For the newest picks from Zacks Investment Research, download the 7 Best Stocks for the Next 30 Days. Click here for your free report.

• Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report
• Cardinal Health, Inc. (CAH): Free Stock Analysis Report
• West Pharmaceutical Services, Inc. (WST): Free Stock Analysis Report
• Phibro Animal Health Corporation (PAHC): Free Stock Analysis Report